Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancer

HER2-E pCR with anti-HER2-based neoadjuvant therapiesПодробнее

EA1181/CompassHER2 pCR Research Study for HER2-Positive Breast Cancer - Full VideoПодробнее

Independent validation of the HER2DX genomic test in HER2-positive breast cancerПодробнее

#ESMO21 Expert Video Report on HER2-positive early breast cancerПодробнее

Dr. Charles Perou | Distinguished Lectureship in Breast Cancer Research | SABCS 2022Подробнее

Correlation between Trop2 and pCR in patients with HER2-positive early breast cancerПодробнее

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast CancerПодробнее

Dr. Aju Mathew, Assistant Professor of Medicine talking on Breast Cancer at our Foster City LabПодробнее

Her-2 Amplification Assessment in Breast Cancer FFPE Samples: QuantStudio 3D Digital PCR vs. ISHПодробнее

HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studiesПодробнее

Dr. Burris Discusses Recurrence Scores Predicting pCRПодробнее

CALGB 40601 Alliance: impact of dual HER2 targeting on pCRПодробнее

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancerПодробнее

The predictive value of treatment response after neoadjuvant therapyПодробнее

New Perspectives on the Full Spectrum of HER2 Expression in Breast CancerПодробнее

Adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in HER2-positive breast cancerПодробнее

PREDICT+ underestimates survival of patients with HER2+ early breast cancerПодробнее

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancerПодробнее

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in...Подробнее

Optimizing adjuvant treatment in HR+/HER2- early breast cancerПодробнее

Role of HER2 Explored in Breast CancerПодробнее